PAM
LXRX icon

Paradigm Asset Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Paradigm Asset Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-4,100
Closed -$67.4K – 466
2017
Q2 		$67.4K Sell
4,100
-4,300
-51% -$66.6K 0.01% 478
2017
Q1 		$120K Buy
8,400
+300
+4% +$4.45K 0.02% 477
2016
Q4 		$112K Sell
8,100
-200
-2% -$3.21K 0.02% 382
2016
Q3 		$150K Buy
8,300
+300
+4% +$4.83K 0.03% 352
2016
Q2 		$115K Buy
+8,000
New +$109K 0.02% 413

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UIM
USS Investment Management London, United Kingdom $27.8B AUM 39.42% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Paradigm Asset Management's LXRX Position: Q3 2017 in Review

Paradigm Asset Management sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2017, closing a stake of 4,100 shares — an estimated $67.4K sold.

Paradigm Asset Management first reported a position in LXRX in Q2 2016 and held it in 5 quarters. The position peaked at $150K in Q3 2016. 137 funds tracked by Wall St. Rank hold LXRX as of Q3 2017.

  • Paradigm Asset Management reported no remaining Lexicon Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Paradigm Asset Management sold 4,100 Lexicon Pharmaceuticals shares in Q3 2017, an estimated $67.4K.
  • Paradigm Asset Management first reported a position in Lexicon Pharmaceuticals in Q2 2016 and held it in 5 quarters.
  • Paradigm Asset Management's Lexicon Pharmaceuticals position peaked at $150K in Q3 2016.
  • 137 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2017.

Based on Paradigm Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.